...We Welcome You to the Zenith Epigenetics Hub On AGORACOM

Zenith's Lead BET Inhibitor ZEN-3694 is Currently Being Evaluated in a Phase 2 Prostate Cancer Clinical Trial

Free
Message: Zenith share issue

would love to see a major deal with a BP but we have never had one to this point,  It would hugely legitimize the science of Zenith and RVX and would be a good catalyst for share movement for RVX   (IMO)  

Share
New Message
Please login to post a reply